Replies to post #62454 on $heff's $tation of $tocks & $olid DD

[$hylo]

APPY..The Head of Regulatory Affairs for APPY, Glen Paul Freiberg has served several terms as the industry representative on FDA Advisory Panels.

Mr. Freiberg is leading regulatory affairs for AspenBio as well as supporting compliance and clinical programs. He began his career as an FDA investigator and worked in areas regulated by three FDA centers (Drugs, Biologics, and Medical Devices). He has served several terms as the industry representative on FDA Advisory Panels. Mr. Freiberg was the head of Regulatory Affairs and Quality for Gen-Probe and oversaw the development and launch of the amplified nucleic acid test for HIV and Hepatitis in donor blood.
http://www.aspenbiopharma.com/management_team.html

This could be very beneficial and positive for APPY as they are about to commence patient enrollment for their Pivotal Clinical Trial and also in anticipation of their CE mark by year end.

[crudeoil24]

APPY (2.51) > Company is in major growth with catalysts EOY.


Gained Nasdaq compliance.
http://bit.ly/MXBoDl

A LOW FLOATER with pending catalyst. They expect their CE Mark at year's end.
http://aspenbiopharma.com/video_ip.html

http://aspenbioinc.investorroom.com/2012-09-27-AspenBio-Plans-to-Initiate-Pivotal-Study-in-Fourth-Quarter

http://finviz.com/quote.ashx?t=appy

[$heff]

APPY $2.55..$heff Holding & forward-looking event that could move the company significantly higher is the CE Mark. Also starting a pivotal trial in Q4.